Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p406 | Osteoporosis: treatment | ECTS2016

Adherence and persistence to teriparatide treatment in patients attending a specialised Bone Health Service

Steen Georgina , Maher Niamh , Fallon Nessa , Dillon Aoife , Mahon James , Lannon Rosaleen , McCarroll Kevin , Walsh J B , Casey Miriam

Introduction: Osteoporosis affects the bones causing weak or brittle bones and increasing the risk of fracture. Efficacy of anti-osteoporotic treatment is based on drug potency and adherence and persistence. Teriparatide (TPTD) is the first anabolic agent developed for the treatment of osteoporosis. It is usually given as a daily subcutaneous injection for a two-year treatment course.Aim: To evaluate adherence and persistence to TPTD treatment in patient...